Not all leaders are good leaders.Perhaps you’ve lost an important executive or you’re establishing a local leadership team. You know that the leader you choose will have a major impact on the organization. So how can you avoid hiring the…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY MHLW Issues Notification to Clarify Orphan Designation Criteria
January 17, 2024
-
COMMENTARY Introduction of Elective Care to Mark Watershed for Long-Listed Drug Makers
January 17, 2024
-
REGULATORY FY2024 Reform Will Bolster Rewards for Innovation to Eradicate Drug Lag/Loss: LDP Policy Bigwig
January 16, 2024
-
REGULATORY New LLP Coverage Rule Aimed to Transform Industry Rather Than Eke Out Savings: LDP Social Security Chief
January 15, 2024
-
BUSINESS GSK’s Arexvy Hits Market as Japan’s 1st RSV Vaccine
January 15, 2024
-
BUSINESS Ono Poised to Overcome Opdivo Patent Cliff and Go Fully Global under New President
January 12, 2024
-
REGULATORY MHLW Study Underway on Lab Monkey Shortage, Research Team Frets Dependence on Specific Sources
January 11, 2024
-
BUSINESS New LLP Coverage Rule Loathed by Off-Patent Drug Makers but Innovative Players Hail Reform
January 10, 2024
-
REGULATORY Handling of Big-Seller Candidates Is Top Priority as Japan Seeks Good Budget Balance: Minister
January 10, 2024
-
ORGANIZATION FPMAJ Stands Firmly Against Full Implementation of Off-Year Price Revision in FY2025
January 9, 2024
-
BUSINESS Santen, Astellas, 3 More Firms Hit by Manufacturing Delays after Quake
January 9, 2024
-
BUSINESS Equa, Betanis and More Brands Gird for Generic Entry in 2024; Xarelto Contenders Too?
January 5, 2024
-
BUSINESS After New Year’s Quake, Wholesalers See Challenges in Drug Delivery to North Part of Noto Peninsula
January 5, 2024
-
REGULATORY FY2024 Reform Heralds Shift to Funding Cycle within Drug Budget: MHLW Pharma Director
December 28, 2023
-
TRENDS Top 10 Most-Read PHARMA JAPAN Articles in 2023
December 28, 2023
-
BUSINESS Amylyx Gears Up to Bring New ALS Drug to Japan Market: Country Chief
December 27, 2023
-
REGULATORY Japan Officially Drops Japanese PI Requirement before Global Trial Entry
December 26, 2023
-
REGULATORY (Update) Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 25, 2023
-
BUSINESS Sawai Slapped with Biz Improvement Order over Rigged Quality Tests
December 22, 2023
-
ORGANIZATION Reform Package Is “First Step” towards Global Standard, but More Work Remains: JPMA
December 22, 2023
ページ
Earlier this month, Health Minister Keizo Takemi called on the top executives of 13 major generic makers to restructure the industry with a product consolidation target of “around five companies per API.” While a variety of restructuring options are conceivable,…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…